Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML

By Litzow Mr   Dietz Ab   Bulur Pa   Butler Gw   Gastineau Da   Hoering A   Fink Sr   Letendre L   Padley Dj   Paternoster Sf   Tefferi A   Vuk-Pavlović S  

Cytotherapy, Vol. 8, Iss. 3, 2006-05 ,pp. : 290-298

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial

By Van Driessche Ann   Van de Velde Ann   Nijs Griet   Braeckman Tessa   Stein Barbara   De Vries Jolanda   Berneman Zwi   Van Tendeloo Viggo  

Cytotherapy, Vol. 11, Iss. 5, 2009-09 ,pp. : 653-658

Ashgate Publishing Ltd

Access to resources Recommend Favorite

DC-based cancer vaccines: lessons from clinical trials

By Brody JD   Engleman EG  

Cytotherapy, Vol. 6, Iss. 2, 2004-04 ,pp. : 122-127

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation

By Szmania S   Yi Q   Cottler-Fox M   Rosen NA   Freeman J   Kordsmeier BJ   Moreno A   Shi J   Barlogie B   Tricot G   van Rhee F  

Cytotherapy, Vol. 7, Iss. 4, 2005-09 ,pp. : 374-384

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Application of a clinical grade CD34-mediated method for the enrichment of microvascular endothelial cells from fat tissue

By Eikelboom Bc   Slaper-cortenbach Icm   Arts Chp   Groot Phg de   Heijnen-snyder Gj   Blankensteijn Jd  

Cytotherapy, Vol. 6, Iss. 1, 2004-01 ,pp. : 30-42

Ashgate Publishing Ltd

Access to resources Recommend Favorite